FDA Brief

Warning letters Drugs

FDA warning letter to

Nubratori, Inc. dba Nubratori Rx

High riskIssued Jan 22, 2025Posted Apr 15, 2025Center for Drug Evaluation and Research (CDER)

FDA cited Nubratori Rx, a sterile compounding outsourcing facility, for insanitary conditions and manufacturing quality failures that may contaminate its drug products.

What happened

After a July 16 to July 26, 2024 inspection of its Torrance, CA facility, FDA found serious deficiencies, including glove fingertip sampling done after sanitizing and current good manufacturing practice (CGMP) failures in acceptance criteria, sterile procedures, environmental monitoring, cleaning, and component testing. FDA issued a Form FDA 483 and reviewed the company’s responses but found some corrective actions inadequate because supporting documentation was missing.

What FDA found

  1. Sterile drug products were prepared under insanitary conditions because glove fingertip sampling was done after gloves were sanitized, so the results may not show contamination during aseptic work.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  2. The firm did not set adequate acceptance criteria for quality control sampling and testing before approving and releasing drug batches.

    21 CFR 211.165(d)
  3. The firm did not follow written procedures designed to prevent microbiological contamination of drug products intended to be sterile.

    21 CFR 211.113(b)
  4. The firm did not have an adequate system for monitoring environmental conditions in aseptic processing areas.

    21 CFR 211.42(c)(10)(iv)
  5. The firm did not follow written procedures for cleaning and maintaining equipment.

    21 CFR 211.67(b)
  6. The firm did not test each lot of component for possible microbiological contamination before use and did not validate the reliability of its component supplier’s test results.

    21 CFR 211.84(d)(6); 21 CFR 211.84(d)(2)

What FDA wants

Within 15 working days, notify FDA in writing of the specific steps taken to address the violations, prevent recurrence, and include supporting documentation; if the matter cannot be fully addressed in that time, state the reason for delay and the time needed.

Who should pay attention

  • patients receiving compounded sterile drugs
  • health care providers and clinics that buy compounded sterile drugs
  • other outsourcing facilities with similar aseptic processes

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. SCA Pharmaceuticals, LLC

    SCA Pharmaceuticals' sterile compounded drugs were made under unsanitary conditions with serious manufacturing violations, FDA says.

    High risk
  2. Pine Pharmaceuticals, LLC

    FDA cited outsourcing facility Pine Pharmaceuticals in Tonawanda, NY, for insanitary sterile compounding conditions and CGMP failures after a November 2025 inspection.

    High risk
  3. Fagron BV

    FDA warns Fagron's Canton, MA sterile compounding site over airflow, cleaning and investigation failures, prompting a recall.

    High risk
  4. RC Outsourcing, LLC

    FDA warned outsourcing facility RC Outsourcing of Lowellville, Ohio, that its sterile drugs were made under insanitary conditions that risk contamination.

    High risk